Compare SYBT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYBT | IOVA |
|---|---|---|
| Founded | 1904 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2009 | 2008 |
| Metric | SYBT | IOVA |
|---|---|---|
| Price | $69.01 | $3.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $76.00 | $9.00 |
| AVG Volume (30 Days) | 119.3K | ★ 14.0M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 22.11 | 14.84 |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | $47.74 |
| Revenue Next Year | $9.32 | $40.31 |
| P/E Ratio | $56.43 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $1.64 |
| 52 Week High | $83.83 | $5.63 |
| Indicator | SYBT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 45.56 |
| Support Level | $67.32 | $3.23 |
| Resistance Level | $71.41 | $4.27 |
| Average True Range (ATR) | 1.78 | 0.25 |
| MACD | -0.49 | -0.01 |
| Stochastic Oscillator | 8.39 | 19.89 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.